COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...

As of 12:32:25 pm GMT+2. Market open. (Bloomberg) -- Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial.Most ...

LONDON & NEW YORK, July 22, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

COMPASS Pathways plc (CMPS) has filed for up to 40,089,163 share offering by selling stockholders.

COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. We recently ...

COMPASS Pathways plc misses on earnings expectations. Reported EPS is $-0.38 EPS, expectations were $-0.37. Operator: Hello, everyone, and welcome to COMPASS Pathways Second Quarter 2025 Earnings ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

A look at the shareholders of COMPASS Pathways plc (NASDAQ:CMPS) can tell us which group is most powerful. The group holding the most number of shares in the company, around 32% to be precise, is ...

COMPASS Pathways plc misses on earnings expectations. Reported EPS is $-1.44451 EPS, expectations were $-0.4. Operator: Good morning, ladies and gentlemen, and thank you for standing by. My name is ...

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. COMPASS Pathways Plc is one of them. COMPASS Pathways Plc (NASDAQ:CMPS), a biotechnology company specializing in ...

All right. Good morning, everyone. Welcome to the session of the Morgan Stanley Global Healthcare Conference. I'm Judah Frommer, one of the SMID biotech analysts here. I'm just going to start off with ...